MNOV - NASDAQ

MediciNova, Inc.

MediciNova, Inc.

MNOV·NASDAQ

$1.34

+0.045%
HealthcareBiotechnology

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$65.96M
EPS-0.2400
P/E Ratio-5.58
Earnings Date08/13/2026

mnov

Depreciation and Amortization

Last Annual Value

20.10K

3-Year CAGR

4%

5-Year CAGR

-1%

10-Year CAGR

-3%

MediciNova, Inc.

MediciNova, Inc. Competitors Analysis of Depreciation and Amortization

MNOV · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
20.10K
-0.3%-5.1%3.6% 
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
168.00K
14.8%14.6%-21.1%
ALGS logo
Aligos Therapeutics, Inc.
NASDAQ:ALGS
930.00K
-32.8%-24.4%N/A
ESLA logo
Estrella Immunopharma, Inc.
NASDAQ:ESLA
0.00
N/AN/AN/A
INKT logo
MiNK Therapeutics, Inc.
NASDAQ:INKT
181.75M
861.3%371.5%N/A
NRXP logo
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
143.00K
205.8%134.9%N/A
CUE logo
Cue Biopharma, Inc.
NASDAQ:CUE
958.00K
-34.7%N/A16.8%
OSTX logo
OS Therapies Incorporated
NYSE:OSTX
2.78K
-13.0%28.1%N/A
VTVT logo
vTv Therapeutics Inc.
NASDAQ:VTVT
16.00K
-43.8%-29.1%-24.5%
BMEA logo
Biomea Fusion, Inc.
NASDAQ:BMEA
1.41M
-2.4%8.1%N/A
RLMD logo
Relmada Therapeutics, Inc.
NASDAQ:RLMD
0.00
N/AN/AN/A
MediciNova, Inc.

MediciNova, Inc. Fair Value Envelope

MNOV · NASDAQ

Our analysis suggests that MNOV has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.34, this represents a potential HIDDEN relative to our calculated worth for MediciNova, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.34

Related Guides

Blog Categories

Continue your MNOV research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.